Drawing for Serial No. 98912317

USPTO serial 98912317

Serial No. 98912317

Reviewed by CopyMark Law Group

Status 731Notice of Allowance
Filing date
Status date
Registration date
—
Examiner
PEISECKI, MARK A
Law office
INTENT TO USE SECTION

What this means

The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.

Status 731: Status 731 means the second six-month extension to file a Statement of Use was granted. File a Statement of Use or the next extension before the deadline expires.

Need help with Serial No. 98912317?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $349*

Plus Government fees of $150

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maury M. Tepper, III

Maury M. Tepper, III Tepper & Eyster, PLLC3724 Benson DriveRaleigh, NC 27609United States

Goods and services

ClassDescriptionStatusFirst use
005Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthmaACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 1, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 31, 2026EX2GSOU EXTENSION 2 GRANTED—
Oct 31, 2026EXT2SOU EXTENSION 2 FILED—
Oct 31, 2026EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 29, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 28, 2026EX1GSOU EXTENSION 1 GRANTED—
Apr 28, 2026EXT1SOU EXTENSION 1 FILED—
Apr 28, 2026EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 4, 2025NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Sep 9, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 9, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 3, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 11, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 11, 2025XAECEXAMINER'S AMENDMENT ENTERED—
Aug 11, 2025GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Aug 11, 2025GNEAEXAMINERS AMENDMENT E-MAILED—
Aug 11, 2025CNEAEXAMINERS AMENDMENT -WRITTEN—
Aug 2, 2025DOCKASSIGNED TO EXAMINER—
Aug 1, 2025MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Aug 1, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 19, 2024NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance